• Antonio Gatti, Alessandro Fabrizio Sabato, Roberto Occhioni, Gianni Colini Baldeschi, and Carlo Reale.
• Dipartimento AFA Servizio di Anestesia e Terapia del Dolore, Ospedale Tor Vergata, Viale Oxford 81, Rome, Italy. antonio.gatti@ptvonline.it
• Eur. Neurol. 2009 Jan 1;61(3):129-37.

AimsThe aim of our study was to compare the efficacy, safety, and quality of life of combination therapy with controlled-release (CR) oxycodone plus pregabalin versus monotherapy with either CR oxycodone or pregabalin in patients with neuropathic pain.Materials And MethodsPatients with moderate to severe neuropathic pain, despite the use of various pharmacologic treatments prior to study entry, were enrolled (n = 409) and treated with CR oxycodone plus pregabalin (n = 169), CR oxycodone (n = 106), and pregabalin (n = 134). Pain intensity was rated on an 11-point numerical rating scale (NRS).ResultsThe combination of CR oxycodone plus pregabalin and CR oxycodone monotherapy were both more effective for alleviating neuropathic pain than pregabalin monotherapy (reduction in NRS value: 80, 76, and 46%, respectively; p ConclusionsThe combination of CR oxycodone plus pregabalin may represent a valuable addition to the existing pharmacotherapy for neuropathic pain and warrants further investigation.Copyright (c) 2008 S. Karger AG, Basel.

28 keywords...

hide…